Anzeige
Erschienen in:
01.10.2018 | Original Article
Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data
Erschienen in: Journal of Nephrology | Ausgabe 5/2018
Einloggen, um Zugang zu erhaltenAbstract
Background
In recent years, novel anticoagulant drugs have been introduced in the clinical armamentarium and have progressively gained momentum. Although their use is increasing among CKD patients, some skepticism about their risk–benefit ratio still persists. We sought to investigate the safety and effectiveness of rivaroxaban in a cohort of moderate-to-advanced CKD patients.
Methods
This observational, retrospective, longitudinal study involved 347 consecutive CKD stage 3b–4 (according to NKF–KDOQI guidelines) patients enrolled from 8 cardiac outpatient clinics between March 2015 and October 2017. All patients received anticoagulation (100 warfarin vs. 247 rivaroxaban) as part of their non-valvular atrial fibrillation management at the attending physician’s discretion. Clinical effectiveness (defined as the occurrence of ischemic stroke, venous thromboembolism, or transient ischemic attack) and safety (intracranial hemorrhage, gastrointestinal or other bleeding) were assessed separately.
Results
Over a mean follow-up period of 16 ± 0.3 months, 25 stroke episodes (15 hemorrhagic, and 10 ischemic) occurred in 24 warfarin treated patients vs. none in the rivaroxaban arm. There were 5 vs. 0 episodes of deep venous thrombosis and 8 vs. 2 major episodes of bleeding in the warfarin and rivaroxaban groups, respectively. In contrast, the proportion of minor episodes of bleeding was similar between groups.
Conclusion
Rivaroxaban seems a safe and effective therapeutic option in CKD stage 3b–4 patients. However, future randomized controlled trials are needed to definitively establish the role of rivaroxaban in CKD patients.